Editor's Choice in Cancer Immunology
Explore the latest breakthroughs in cancer immunology with our curated selection of Editor's Choice articles from the esteemed Editors-in-Chief of Cellular Immunology, Clinical Immunology, and Immunobiology.
These studies provide valuable insights into the complex interactions between the immune system and cancer, paving the way for innovative therapeutic strategies.
Cellular Immunology
Selected by the Co-Editors-in-Chief Dr. Simon Fillatreau and Dr. Yi Hao
Macrophage niche imprinting as a determinant of macrophage identity and function S’ouvre dans une nouvelle fenêtre This study elucidates the role of the tissuemicroenvironment in shaping macrophage identity and functionality.Understanding these mechanisms is crucial for developing targeted therapiesthat harness macrophage capabilities in cancer treatment.
MALT1 inhibition suppresses antigen-specific T cell responses S’ouvre dans une nouvelle fenêtre Investigating the impact of MALT1 on T cellresponses, this research highlights a novel approach to modulating immuneresponses in tumors, presenting new avenues for enhancing immunotherapyefficacy.
HLA-class-I expression loss, tumor microenvironment and breast cancer prognosis S’ouvre dans une nouvelle fenêtre The loss of HLA-class-I expression in breastcancer is linked to a more immunosuppressive tumor microenvironment. Thisfinding emphasizes the importance of immune evasion in cancer prognosis andpotential therapeutic targets.
Immunomodulation by galectin-9: Distinct role in T cell populations, current therapeutic avenues and future potential S’ouvre dans une nouvelle fenêtre This review explores how Galectin-9 influences Tcell dynamics within the tumor microenvironment, offering insights into itstherapeutic potential in cancer immunotherapy.
Clinical Immunology
Selected by the Co-Editors-in-Chief Dr. Samia Khoury and Dr. Antonio La Cava
Tumor cell-derived LC3B+extracellular vesicles mediate the crosstalk between tumor microenvironment and immunotherapy efficacy in hepatocellular carcinoma via the HSP90α-IL-6/IL-8 signaling axis S’ouvre dans une nouvelle fenêtre This groundbreaking study reveals howextracellular vesicles from tumor cells can modulate the tumormicroenvironment, impacting the efficacy of immunotherapy in liver cancer. Thefindings open up new strategies for improving treatment outcomes.
Oxidative stress is involved in immunosuppression and macrophage regulation in glioblastoma S’ouvre dans une nouvelle fenêtre Investigatingthe role of oxidative stress in glioblastoma, this research sheds light on howit contributes to immune evasion and macrophage polarization, highlightingpotential therapeutic interventions targeting oxidative pathways.
Immunobiology
Selected by the Editor-in-Chief Dr. Viviana Ferreira
Nucleotide receptor P2X7/STAT6 pathway regulates macrophage M2 polarization and its application in CAR-T immunotherapy S’ouvre dans une nouvelle fenêtre This study identifies the P2X7/STAT6 signalingpathway as a critical regulator of macrophage polarization, suggesting thatmodulation of this pathway could enhance the effectiveness of CAR-T celltherapies.
APOE Drives Glioma Progression by Modulating CCL5/CCR5 Signaling in the Tumor Microenvironment and Inducing M2 Macrophage Polarization S’ouvre dans une nouvelle fenêtre Exploring the role of APOE in glioma, thisresearch uncovers its influence on macrophage polarization and tumorprogression, providing insights into potential targets for therapeuticintervention.
Circulating Tfh cells and Tfr cells in papillary thyroid carcinoma and their diagnostic potential S’ouvre dans une nouvelle fenêtre This study assesses the relevance of Tfollicular helper and regulatory cells in the context of papillary thyroidcarcinoma, revealing their potential as biomarkers for diagnosis and prognosis.
High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer S’ouvre dans une nouvelle fenêtre Highlighting a novel interaction between VitaminC and immune checkpoint regulation, this research suggests that high-doseVitamin C could serve as an adjunct therapy to enhance the effectiveness ofPD-1/PD-L1 blockade in colorectal cancer.
Stay informed
Thesearticles represent just a fraction of the cutting-edge research that is shapingthe future of cancer immunology. Visit our journal homepages to explore moreand submit your own research contributions!